Giulio Metro

5.7k total citations
169 papers, 3.3k citations indexed

About

Giulio Metro is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Giulio Metro has authored 169 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Oncology, 130 papers in Pulmonary and Respiratory Medicine and 45 papers in Molecular Biology. Recurrent topics in Giulio Metro's work include Lung Cancer Treatments and Mutations (102 papers), Lung Cancer Research Studies (55 papers) and Cancer Immunotherapy and Biomarkers (32 papers). Giulio Metro is often cited by papers focused on Lung Cancer Treatments and Mutations (102 papers), Lung Cancer Research Studies (55 papers) and Cancer Immunotherapy and Biomarkers (32 papers). Giulio Metro collaborates with scholars based in Italy, United States and Switzerland. Giulio Metro's co-authors include Lucio Crinò, Rita Chiari, Biagio Ricciuti, Alessandra Fabi, Sara Baglivo, Francesco Cognetti, Vienna Ludovini, Andrea De Giglio, Federico Cappuzzo and Marta Brambilla and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Giulio Metro

165 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Giulio Metro Italy 33 2.2k 1.8k 1.0k 573 302 169 3.3k
Thomas Bachelot France 28 1.5k 0.7× 855 0.5× 1.0k 1.0× 858 1.5× 236 0.8× 130 3.0k
Hiroyasu Kaneda Japan 30 2.3k 1.1× 1.6k 0.9× 1.1k 1.1× 445 0.8× 144 0.5× 118 3.5k
Vincenzo Damiano Italy 26 1.9k 0.9× 1.2k 0.6× 1.4k 1.3× 459 0.8× 179 0.6× 62 3.2k
Christina S. Baik United States 27 2.1k 1.0× 1.8k 1.0× 1.3k 1.3× 685 1.2× 148 0.5× 116 3.5k
Jean‐Sébastien Frenel France 26 1.4k 0.6× 809 0.4× 801 0.8× 708 1.2× 354 1.2× 188 2.7k
Ernest Nadal Spain 34 1.8k 0.8× 1.8k 1.0× 1.5k 1.5× 815 1.4× 121 0.4× 169 3.6k
Rita Chiari Italy 36 2.6k 1.2× 2.4k 1.3× 1.4k 1.4× 900 1.6× 129 0.4× 140 4.2k
Simon Ekman Sweden 25 2.2k 1.0× 2.5k 1.3× 1.4k 1.4× 1.0k 1.8× 137 0.5× 116 4.2k
Biagio Ricciuti United States 33 2.6k 1.2× 1.7k 0.9× 1.1k 1.0× 774 1.4× 133 0.4× 161 3.8k
Vienna Ludovini Italy 33 2.1k 1.0× 2.0k 1.1× 1.3k 1.3× 900 1.6× 95 0.3× 102 3.5k

Countries citing papers authored by Giulio Metro

Since Specialization
Citations

This map shows the geographic impact of Giulio Metro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulio Metro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulio Metro more than expected).

Fields of papers citing papers by Giulio Metro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giulio Metro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulio Metro. The network helps show where Giulio Metro may publish in the future.

Co-authorship network of co-authors of Giulio Metro

This figure shows the co-authorship network connecting the top 25 collaborators of Giulio Metro. A scholar is included among the top collaborators of Giulio Metro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulio Metro. Giulio Metro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ricciuti, Biagio, Rohit Thummalapalli, Fabrizio Citarella, et al.. (2024). Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade.. Journal of Clinical Oncology. 42(16_suppl). 8633–8633.
2.
Ghigna, Maria‐Rosa, Filippo Gustavo Dall’Olio, Martina Mandarano, et al.. (2023). 2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC. Annals of Oncology. 34. S1197–S1198. 1 indexed citations
3.
Andrini, Elisa, et al.. (2022). Non-small-cell lung cancer: how to manage RET-positive disease. Drugs in Context. 11. 1–12. 10 indexed citations
4.
Tsagkaris, Christos, et al.. (2022). Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. Cancers. 14(14). 3337–3337. 50 indexed citations
5.
Pierini, Valentina, Paolo Gorello, Giovanni Roti, et al.. (2020). New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma. Acta Neuropathologica Communications. 8(1). 145–145. 22 indexed citations
6.
Genova, Carlo, Simona Coco, Giovanni Rossi, et al.. (2020). 1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer. Annals of Oncology. 31. S825–S826. 2 indexed citations
7.
Friedlaender, Alex, Stephen V. Liu, Antonio Passaro, et al.. (2020). The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. Clinical Lung Cancer. 21(6). e539–e543. 16 indexed citations
8.
Ricciuti, Biagio, et al.. (2019). 進行を超えて治療した進行性非小細胞肺癌患者におけるニボルマブの安全性と有効性【JST・京大機械翻訳】. Clinical Lung Cancer. 20(3). 178–185. 4 indexed citations
9.
Ludovini, Vienna, Biagio Ricciuti, Francesca Romana Tofanetti, et al.. (2018). KRAS mutation and DNA repair and synthesis genes in non‑small‑cell lung cancer. Molecular and Clinical Oncology. 9(6). 689–696. 7 indexed citations
10.
Ricciuti, Biagio, Carlo Genova, Andrea De Giglio, et al.. (2018). Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Journal of Cancer Research and Clinical Oncology. 145(2). 479–485. 264 indexed citations
11.
Rebonato, Alberto, Luigina Graziosi, Daniele Maiettini, et al.. (2017). Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Gastroenterology Research and Practice. 2017. 1–9. 11 indexed citations
12.
Maiettini, Daniele, Verena De Angelis, Luigina Graziosi, et al.. (2016). Sacrum colon-rectal cancer metastasis: microwave ablation for palliative pain treatment. Recenti Progressi in Medicina. 107(12). 673–676. 3 indexed citations
13.
Mandarano, Martina, Biagio Ricciuti, Rita Chiari, et al.. (2016). Müllerian Tumor Originating from the Pleura in a 47-Years Old Woman: A Case Report. 1(1). 1 indexed citations
14.
Ricciuti, Biagio, Giulia C. Leonardi, Giulio Metro, et al.. (2015). Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine. 10(1). 53–68. 52 indexed citations
15.
Ricciuti, Biagio, Giulio Metro, Piero Ferollà, et al.. (2015). Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received: a single institution analysis. Annals of Oncology. 26. vi78–vi78. 2 indexed citations
16.
Bennati, Chiara, Dara L. Aisner, Rita Chiari, et al.. (2013). Identification of Targetable Driver Mutations In Molecularly Selected Never Smoker Lung Adenocarcinomas. Journal of Thoracic Oncology. 8. 1 indexed citations
17.
Fabi, Alessandra, Anna Di Benedetto, Giulio Metro, et al.. (2011). HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. Clinical Cancer Research. 17(7). 2055–2064. 72 indexed citations
18.
Metro, Giulio, Jennifer Foglietta, Michelangelo Russillo, et al.. (2010). Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Annals of Oncology. 22(3). 625–630. 120 indexed citations
19.
Metro, Giulio, Diana Giannarelli, Gaetano Lanzetta, et al.. (2009). Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer. The Breast Journal. 16(1). 66–72. 10 indexed citations
20.
Metro, Giulio, Alessandra Fabi, Michelangelo Russillo, et al.. (2008). Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.. PubMed. 28(2B). 1245–58. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Bachelot Breakdown of academic impact, for papers by Hiroyasu Kaneda Breakdown of academic impact, for papers by Vincenzo Damiano Breakdown of academic impact, for papers by Christina S. Baik Breakdown of academic impact, for papers by Jean‐Sébastien Frenel Breakdown of academic impact, for papers by Ernest Nadal Breakdown of academic impact, for papers by Rita Chiari Breakdown of academic impact, for papers by Simon Ekman Breakdown of academic impact, for papers by Biagio Ricciuti Breakdown of academic impact, for papers by Vienna Ludovini
Rankless by CCL
2026